Home » Newsletters » BioWorld Science

BioWorld Science

April 29, 2005

View Archived Issues

Senetek completes Zeatin preclinical studies

Phase II PEAK study begins for Velcade in lung cancer

Calpain: a potential target for the treatment of diabetic vascular complications

Virax advances HIV/AIDS Co-X-Gene programs

Phase III trial studies panitumumab for first-line treatment of colorectal cancer

Phase I study assesses MT-201 with Taxotere for breast cancer treatment

Gilead progresses new fixed-dose combination of Truvada and Sustiva

Encysive restructures agreement with Revotar

Maxim receives milestone payment under agreement with Myriad Genetics

Bentley and Dong Sung sign agreement for intranasal insulin in South Korea

Alzhemed phase III trial recommended to continue

Aloxi receives European approval

Daiichi terminates TZT-1027 licensing agreement with Teikoku Hormone

Dosing under way in phase I/II trial of ImmunoVEX-Trimelan

New phase I trial of TST-10088 in advanced solid tumor patients

NDA for tetrabenazine for chorea associated with Huntington's disease

Novel antiinfective agents disclosed in recent patent literature

Compounds for treatment of Flaviviridae infections reported

New agents claimed for the treatment of lipoprotein disorders, obesity, etc.

Update on atosiban in the management of dysmenorrhea and preterm labor

One-year results of the RIO-Europe study support the use of rimonabant in obesity

Significant protection against HPV infection achieved with Gardasil in young women

CHEC-9 blocks sPLA2 activity in vitro and in vivo / News in Context

Effective post-exposure therapy against West Nile virus in mice

Hayashibara claims novel therapeutic agents for osteoporosis

CR-064 neutralizes procancerous actions of ARP4

Nonpeptide Smac mimetics represent a novel class of anticancer agents

Novel beta-catenin inhibitors delay the growth of colon cancer tumors in mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 9, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...